About KALA BIO Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.kalarx.com/
Frequently Asked Questions
What is the 52-week range for KALA?
The 52-week high is $95.5 and the 52-week low is $0.401.
What is the P/E ratio for KALA?
The P/E ratio data is currently unavailable.
What is the dividend yield for KALA?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -28.16%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -1383.48%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 3.43.
Analyst Recommendation Trends
Wall Street analyst consensus for KALA over the last few months:
Latest KALA News
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Elutia (NASDAQ:ELUT) stock moved upwards by 17.2% to $0.94 during Thursday's after-market session. The market value of their outstanding shares is at $34.9 million. Intelligent Bio Solutions (NASDAQ:INBS)
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Monte Rosa Therapeutics (NASDAQ:GLUE) stock rose 9.7% to $13.09 during Wednesday's after-market session. The company's market cap stands at $1.0 billion. Filana Therapeutics (NASDAQ:FLNA) shares rose
Why FingerMotion Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
FingerMotion jumped 18.1% premarket after agreeing to buy Newbit Technology for $2.3M cash; NewGenIvf led gainers at 187.2%, while Silexion fell 16.6%.
KALA Bio (KALA) Shares Soar 57% After Hours: Here's Why
KALA Bio shares surge after hours after signing an LOI to acquire a nationwide telehealth platform.
KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception
Proposed Acquisition Valued at Approximately $15 Million Would Add an Established 50-State Telehealth Business, with over 90,000 clients, Focused on Peptides such as GLP-1 Weight Management, Hormone Health, Longevity and Sexual WellnessKey HighlightsTarget generated approximately $12.7 million in revenue for the trailing twelve months ended August 2026 (unaudited, as provided by Target management) and is cash-flow positiveProposed purchase price of approximately $15 million, payable in cash and.
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Silexion Therapeutics (NASDAQ:SLXN) shares rose 26.8% to $0.32 during Tuesday's pre-market session. The company's market cap stands at $1.3 million. Summit Therapeutics (NASDAQ:SMMT) stock rose 16.34%
KALA Bio Inks Letter Of Intent To Acquire U.S.-Based Management Services Firm For ~$15M
KALA Bio, Inc. (NASDAQ:KALA) ("KALA" or the "Company") today announced that on September 24, 2026, it signed a non-binding letter of intent ("LOI") for the proposed acquisition of 100% of a
Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products
Agreement would expand the companies' genetic testing collaboration beyond ophthalmology to a selected suite of genomic testing products through an additional U.S. reseller channelARLINGTON, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Kala Bio, Inc. (Nasdaq: KALA) ("Kala") and Virotek Inc. ("Virotek") today announced that they have signed a non-binding letter of intent (the "LOI") with a U.S. DNA testing platform under which the platform would resell Virotek's selected suite of genomic testing pro
KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory Team
Founder of The LSM Group to support KALA's growth across its existing business and potential acquisitionsNEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq: KALA) ("KALA" or the "Company") today announced that Yenvy Truong, founder of The LSM Group, has joined the Company's advisory team. Ms. Truong will support management as KALA grows its existing business and evaluates opportunities to expand it, including through acquisitions. Ms. Truong has spent roughly two decades in heal
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2025-12-18 | Lazar David E. | -368,614 | - | - |
| 2025-11-24 | Lazar David E. | +900,000 | - | - |
| 2025-10-23 | Reumuth Mary | -967 | $0.82 | $793 |
| 2025-10-23 | Iwicki Mark T | -154,894 | $0.81 | $125,464 |
| 2025-10-22 | Brazzell Romulus K | -46,748 | $0.83 | $38,801 |
| 2025-10-22 | Kharabi Darius | -20,806 | $0.83 | $17,269 |
| 2025-10-22 | Reumuth Mary | -32,230 | $0.83 | $26,751 |
| 2025-10-22 | Bazemore Todd | -47,768 | $0.83 | $39,647 |